Navigation Links
Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Date:9/6/2013

PALO ALTO, Calif., Sept. 6, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.

"We are very pleased with the results of the trial thus far and we look forward to the full data readout before the end of the year," said Wei (William) Cao, PhD, BM, President at Cellular Biomedicine Group. "Knee osteoarthritis severely impacts one's quality of life, and surgical treatment is very costly and invasive. This trial's preliminary results have encouraged us to continue with the study to further test the efficacy of this hopeful therapy to reduce pain, repair knee cartilage and improve quality of life of the patients in the next Phase II trial."

Knee Osteoarthritis in China
There are approximately 57 million people in China suffering from knee osteoarthritis. As drug-based methods of management are ineffective, many patients with this disease will degenerate to the point of requiring invasive artificial joint replacement surgery.

About the Clinical Trial
Cellular Biomedicine Group's Phase I/IIa clinical trial studies the safety and efficacy of CBMG's proprietary adipose-derived progenitor cell (haMPC) - based therapy for knee osteoarthritis. According to the interim analysis of Phase I/IIa for KOA, 24 patie
'/>"/>

SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cellular Dynamics Launches MyCell™ Services
2. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
3. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
4. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
5. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
6. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
9. Cellular Biomedicine Group Marks the Launch of China Clinical Trial for TC-DC Therapy for Hepatocellular Carcinoma
10. Cellular Dynamics International Opens Facility in California, Leasing Space from the Buck Institute to Derive and Bank Human Induced Pluripotent Stem Cells
11. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
(Date:4/20/2015)... , April 20, 2015 Research published today ... of Sciences (PNAS) demonstrates that technology invented ... Casey Eye Institute can improve the ... Optical coherence tomography (OCT) angiography could largely replace ... diseases. OHSU researchers found that OCT ...
(Date:4/20/2015)... BILLERICA, Mass. , April 20, 2015 /PRNewswire/ ... tools for cell metabolism research, introduces the XFp ... a unique real-time assay on live cells that ... one-hour test measures both the mitochondrial and glycolytic ... values with metabolic activity under stressed conditions, induced ...
Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5New XFp Cell Energy Phenotype Test Determines Metabolic Potential 2New XFp Cell Energy Phenotype Test Determines Metabolic Potential 3
... As previously announced, primary endpoint not met; ... with ERBITUX,-, NEW YORK, April 16, 2007 ... Company today,announced detailed results from the EPIC ... trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan to ...
... WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), a ... primarily for cancer treatment, today announced that ... the 98th Annual Meeting,of the American Association ... also disclosed that its April 2005 discovery,collaboration ...
Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
(Date:4/21/2015)... (PRWEB) April 21, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the William and Ida ... Hill, NC 27599. More than 50 hospitals, clinics and groups ... All specialties will be represented. Attendees will enjoy free hors ... Career Fairs for PracticeMatch says “Chapel Hill is ...
(Date:4/21/2015)... United Benefit Advisors (UBA), the nation’s ... to welcome Power Kunkle Benefits Consulting as its ... Jeff Power have been committed to providing the ... more than 450 clients. For Power Kunkle Benefits ... stewardship, ethical consulting, and measurable results. , ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
(Date:4/21/2015)... Nashville, Tenn. – Radsource, a leader ... Archiving and Communication Systems (PACS), has expanded its ... the first quarter of 2015. , Kentucky Breast ... and Lowcountry Orthopaedics & Sports Medicine (Charleston, SC) ... services. Mt. San Rafael Hospital (Trinidad, CO) will ...
(Date:4/21/2015)... Timonium, Maryland (PRWEB) April 21, 2015 eSight ... who are legally blind to see and, on Tuesday, May ... (LVS of MD & VA) will host an unveiling ... Timonium, MD office. LVS of MD & VA will be ... eyewear. A limited number of individual patient demonstrations will be ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... Steps To Serve Your Champagne This Holiday With Style And ... Ease - And Most Importantly ... ,There,s nothing that brings a little sparkle to your holiday ... Americans will,consume more than 900 million glasses of champagne this ...
... Calif., Dec. 21 Pharmacyclics,Inc. (Nasdaq: PCYC ) ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of non-small cell lung cancer (NSCLC) patients ... combination with whole brain,radiation therapy (WBRT) was filed with ...
... 21 Biodel Inc. (Nasdaq:,BIOD) today announced that Dr. ... corporate update at the 26th Annual JPMorgan Healthcare,Conference on ... The JPMorgan Healthcare Conference will be held January ... Francisco, California., Interested parties may access a link ...
... Center receives shipment milestone - expanding, their depth ... SET technologies, IRVINE, Calif., Dec. 21 ... Read-Through Motion and Low,Perfusion pulse oximetry, today announced ... bedside pulse oximeter (excluding hand-held units) to,Alta Bates ...
... Contest Urges Young People to Promote Home,Safety, ... has named the winners of its 2008 National ... States Environmental Protection,Agency. First-place winner is Sara Garcia, ... Science in Hollywood, Florida; second-place winner is,Daniel Carr, ...
... Ireland Cancer Center of University Hospitals Case Medical Center, in ... the Cancer Research Network, found that the majority of older ... the standard of treatment five years of daily oral ... the February issue of Journal of Clinical Oncology and released ...
Cached Medicine News:Health News:Five Steps to Pop the Cork - Not Your Eye Out 2Health News:Five Steps to Pop the Cork - Not Your Eye Out 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 2Health News:Biodel Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 7th, 2008 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 2Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 3Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 4Health News:Masimo Celebrates 500,000th Pulse Oximeter Shipped 5Health News:National Safety Council Names Winners of Radon Poster Contest 2Health News:Ireland Cancer Center researcher finds standard treatment for breast cancer not followed 2
Aluminum english and metric ruler. 1 3/8 inche wide....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: